{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T13:08:28Z","timestamp":1779973708774,"version":"3.53.1"},"reference-count":110,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.amjcard.2026.03.058","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T17:11:59Z","timestamp":1774545119000},"page":"58-70","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Beyond Percutaneous Coronary Intervention - Targeted Molecular Therapies for the Next Era of Coronary Care"],"prefix":"10.1016","volume":"269","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6374-1821","authenticated-orcid":false,"given":"Mihail","family":"Celeski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Golino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Maria Di","family":"Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bernardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Lo Sasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Di Gioia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio Giuseppe","family":"Biccir\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Popolo Rubbio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Vecchione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Cesaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Polimeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Mollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Testa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2026.03.058_bib0001","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.037203","article-title":"Multi-omic insight into the molecular networks in the pathogenesis of coronary artery disease","volume":"14","author":"Fang","year":"2025","journal-title":"JAHA"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0002","doi-asserted-by":"crossref","first-page":"zwaf693","DOI":"10.1093\/eurjpc\/zwaf693","article-title":"Polygenic risk score for coronary artery disease across the spectrum of atherosclerotic disease","author":"Zimerman","year":"2025","journal-title":"Eur J Prevent Cardiol"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0003","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.atherosclerosis.2021.08.020","article-title":"Polygenic risk score and coronary artery disease: a meta-analysis of 979,286 participant data","volume":"333","author":"Agbaedeng","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0004","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/eurheartj\/ehad161","article-title":"Proteomics and lipidomics in atherosclerotic cardiovascular disease risk prediction","volume":"44","author":"Nurmohamed","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0005","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1186\/s12967-025-06425-2","article-title":"Machine learning and multi-omics integration: advancing cardiovascular translational research and clinical practice","volume":"23","author":"Lin","year":"2025","journal-title":"J Transl Med"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0006","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1093\/eurheartj\/ehaa082","article-title":"Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials","volume":"41","author":"Marsico","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0007","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s12933-025-02840-3","article-title":"Glucagon-like peptide-1 receptor agonist in myocardial infarction and atherosclerotic cardiovascular disease risk reduction: a comprehensive meta-analysis of number needed to treat, efficacy and safety","volume":"24","author":"Tang","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0008","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.3390\/jcm13051251","article-title":"Novel and emerging LDL-C lowering strategies: a new era of dyslipidemia management","volume":"13","author":"Agnello","year":"2024","journal-title":"JCM"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0009","article-title":"Fusion modeling: combining clinical and imaging data to advance cardiac care","volume":"16","author":"Van Assen","year":"2023","journal-title":"Circ: Cardiovascular Imaging"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0010","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1161\/ATVBAHA.124.319980","article-title":"Novel therapeutics and upcoming clinical trials targeting inflammation in cardiovascular diseases","volume":"44","author":"Potere","year":"2024","journal-title":"ATVB"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0011","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.3390\/life13081669","article-title":"Novel anti-inflammatory therapies in coronary artery disease and acute coronary syndromes","volume":"13","author":"Dimitroglou","year":"2023","journal-title":"Life"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0012","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1161\/ATVBAHA.118.310955","article-title":"Novel antiplatelet therapies for atherothrombotic diseases","volume":"39","author":"Majithia","year":"2019","journal-title":"ATVB"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0013","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1093\/eurheartj\/ehab027","article-title":"Coronary stent CD31-mimetic coating favours endothelialization and reduces local inflammation and neointimal development in vivo","volume":"42","author":"Diaz-Rodriguez","year":"2021","journal-title":"European Heart Journal"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0014","doi-asserted-by":"crossref","DOI":"10.36660\/abc.20240252","article-title":"Escores de Risco Polig\u00eanico: O Pr\u00f3ximo Passo para Melhorar a Estratifica\u00e7\u00e3o de Risco na Doen\u00e7a Arterial Coronariana?","volume":"121","author":"Stein","year":"2024","journal-title":"Arq Bras Cardiol"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0015","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1146\/annurev-med-042921-112629","article-title":"Advances and applications of polygenic scores for coronary artery disease","volume":"74","author":"Patel","year":"2023","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0016","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/ATVBAHA.124.321846","article-title":"Clinical and genomic prediction of coronary artery disease subtypes","volume":"45","author":"Liou","year":"2025","journal-title":"ATVB"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0017","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1186\/s12916-023-03197-8","article-title":"Proteomic insights into the associations between obesity, lifestyle factors, and coronary artery disease","volume":"21","author":"Yang","year":"2023","journal-title":"BMC Med"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0018","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s40364-025-00821-y","article-title":"Trans-omics analyses identify the biochemical network of LPCAT1 associated with coronary artery disease","volume":"13","author":"Hsu","year":"2025","journal-title":"Biomark Res"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.120414","article-title":"Multiomics in atherosclerotic cardiovascular disease","volume":"408","author":"Nordestgaard","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0020","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes","volume":"146","author":"Marx","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0021","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1111\/dom.14079","article-title":"The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials","volume":"22","author":"Leiter","year":"2020","journal-title":"Diabetes Obesity Metabolism"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0022","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1161\/CIRCULATIONAHA.117.028136","article-title":"Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors","volume":"136","author":"Nauck","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0023","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/atv.0000615456.97862.30","article-title":"Endothelial GLP-1 (Glucagon-Like Peptide-1) receptor mediates cardiovascular protection by liraglutide in mice with experimental arterial hypertension","volume":"40","author":"Helmst\u00e4dter","year":"2020","journal-title":"ATVB"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0024","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jcjd.2019.09.003","article-title":"Mechanisms by which glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors reduce cardiovascular risk in adults with type 2 diabetes mellitus","volume":"44","author":"Sharma","year":"2020","journal-title":"Canad J Diabetes"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0025","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"The Lancet"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0026","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0027","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0028","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0029","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s40119-025-00426-4","article-title":"Beyond blood sugar: a scoping review of GLP-1 receptor agonists in cardiovascular care","volume":"14","author":"Gupta","year":"2025","journal-title":"Cardiol Ther"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0030","doi-asserted-by":"crossref","first-page":"zwag077","DOI":"10.1093\/eurjpc\/zwag077","article-title":"Impact of semaglutide on limb events: a meta-analysis of randomized controlled trials","author":"Cesaro","year":"2026","journal-title":"Eur J Prevent Cardiol"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0031","doi-asserted-by":"crossref","first-page":"zwaf257","DOI":"10.1093\/eurjpc\/zwaf257","article-title":"Reduction of new onset of atrial fibrillation in patients treated with semaglutide: an updated systematic review and meta regression analysis of randomized controlled trials","author":"Cesaro","year":"2025","journal-title":"Eur J Prevent Cardiol"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0032","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1056\/NEJMoa2505928","article-title":"Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes","volume":"393","author":"Nicholls","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0033","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/clc.23997","article-title":"Impact of the ultra-long 48 mm drug-eluting stent on procedural and clinical outcomes in patients with diffuse long coronary artery disease","volume":"46","author":"Youn","year":"2023","journal-title":"Clinical Cardiology"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.25259\/IJCDW_63_2024","article-title":"Management of diffuse coronary artery disease with an overview of recent trials","volume":"0","author":"Meenakshi","year":"2026","journal-title":"IJCDW"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0035","article-title":"Physiological pattern of disease assessed by pressure-wire pullback has an influence on fractional flow reserve\/instantaneous wave-free ratio discordance: insights from the multicenter AJIP registry","volume":"12","author":"Warisawa","year":"2019","journal-title":"Circ: Cardiovasc Interventions"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0036","first-page":"2174","article-title":"Functional patterns of coronary disease","volume":"15","author":"Scarsini","year":"2022","journal-title":"JACC: Cardiovasc Interventions"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0037","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ijcard.2022.01.048","article-title":"Single center experience in the treatment of hemodynamically significant diffuse coronary artery disease of the left anterior descending","volume":"352","author":"Van Beek","year":"2022","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0038","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0039","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2023.06.971","article-title":"Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaque","volume":"378","author":"Marfella","year":"2023","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0041","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0042","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3390\/ijms25010328","article-title":"Molecular therapies in cardiovascular diseases: small interfering RNA in atherosclerosis, heart failure, and hypertension","volume":"25","author":"Sarzani","year":"2023","journal-title":"IJMS"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0043","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2025.03.019","article-title":"Design and Rationale of Lp(a)HORIZON Trial: assessing the effect of lipoprotein(a) lowering with pelacarsen on major cardiovascular events in patients with CVD and elevated Lp(a)","volume":"287","author":"Cho","year":"2025","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0044","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.3390\/biomedicines13071723","article-title":"Genomic and precision medicine approaches in atherosclerotic cardiovascular disease: from risk prediction to therapy-a review","volume":"13","author":"Mitsis","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0045","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3390\/cells14020131","article-title":"CRISPR-Cas9 in cardiovascular medicine: unlocking new potential for treatment","volume":"14","author":"Bonowicz","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.engmed.2024.100035","article-title":"Engineering CRISPR for emerging therapeutic applications","volume":"1","author":"Sun","year":"2024","journal-title":"EngMedicine"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0047","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13073-024-01313-8","article-title":"Predicting the presence of coronary plaques featuring high-risk characteristics using polygenic risk scores and targeted proteomics in patients with suspected coronary artery disease","volume":"16","author":"M\u00f8ller","year":"2024","journal-title":"Genome Med"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0048","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41569-025-01191-6","article-title":"Coronary CT angiography evaluation with artificial intelligence for individualized medical treatment of atherosclerosis: a Consensus Statement from the QCI Study Group","volume":"23","author":"Schulze","year":"2026","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0049","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4244\/EIJ-D-20-01355","article-title":"Artificial intelligence and optical coherence tomography for the automatic characterisation of human atherosclerotic plaques","volume":"17","author":"Chu","year":"2021","journal-title":"EuroIntervention"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0050","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41746-023-00880-1","article-title":"CathAI: fully automated coronary angiography interpretation and stenosis estimation","volume":"6","author":"Avram","year":"2023","journal-title":"Npj Digit Med"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0051","doi-asserted-by":"crossref","DOI":"10.1117\/1.JBO.29.3.036004","article-title":"Structurally constrained and pathology-aware convolutional transformer generative adversarial network for virtual histology staining of human coronary optical coherence tomography images","volume":"29","author":"Li","year":"2024","journal-title":"J Biomed Opt"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2024.118621","article-title":"Using omics data and genome editing methods to decipher GWAS loci associated with coronary artery disease","volume":"401","author":"Chignon","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0053","doi-asserted-by":"crossref","DOI":"10.31083\/RCM38705","article-title":"Artificial intelligence in cardiac treatment decision-making: an evaluation of the performance of ChatGPT versus the heart team in coronary revascularization","volume":"26","author":"Mola","year":"2025","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0054","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.amjcard.2022.09.008","article-title":"Comparison of outcomes of invasive or conservative management of chronic coronary disease in four randomized controlled trials","volume":"185","author":"Mavromatis","year":"2022","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0055","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa070829","article-title":"Optimal medical therapy with or without PCI for stable coronary disease","volume":"356","author":"Boden","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0056","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa1915922","article-title":"Initial invasive or conservative strategy for stable coronary disease","volume":"382","author":"Maron","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0057","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176338","article-title":"Hegemony of inflammation in atherosclerosis and coronary artery disease","volume":"966","author":"Attiq","year":"2024","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0058","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1016\/j.jacc.2018.06.082","article-title":"Clinician\u2019s guide to reducing inflammation to reduce atherothrombotic risk","volume":"72","author":"Ridker","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0059","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1093\/eurheartj\/ehaf196","article-title":"Residual cholesterol and inflammatory risk in statin-treated patients undergoing percutaneous coronary intervention","volume":"46","author":"Bay","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0060","first-page":"zwaf112","article-title":"Prognostic impact of residual inflammatory and triglyceride risk in statin-treated patients with well-controlled LDL cholesterol and atherosclerotic cardiovascular disease","author":"Di Muro","year":"2025","journal-title":"Eur J Preventive Cardiol"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0061","first-page":"113","article-title":"Association of plasma interleukin-6 with infarct size, reperfusion injury, and adverse remodelling after ST-elevation myocardial infarction","volume":"11","author":"Tiller","year":"2022","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0062","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jacc.2022.12.021","article-title":"Pericoronary adipose tissue as a marker of cardiovascular risk","volume":"81","author":"Tan","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0063","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1093\/eurheartj\/ehad484","article-title":"Perivascular adipose tissue as a source of therapeutic targets and clinical biomarkers","volume":"44","author":"Antoniades","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0064","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1161\/ATVBAHA.120.312470","article-title":"Perivascular Adipose Tissue and Vascular Perturbation\/Atherosclerosis","volume":"40","author":"Kim","year":"2020","journal-title":"ATVB"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0065","article-title":"Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement","author":"Mensah","year":"2025","journal-title":"JACC"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0066","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0067","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0068","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0069","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1159\/000512772","article-title":"Colchicine for left ventricular infarct size reduction in acute myocardial infarction: a phase II, multicenter, randomized, double-blinded, placebo-controlled study protocol - the COVERT-MI study","volume":"146","author":"Bresson","year":"2021","journal-title":"Cardiology"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0070","article-title":"Effects of acute colchicine administration prior to percutaneous coronary intervention: COLCHICINE-PCI randomized trial","volume":"13","author":"Shah","year":"2020","journal-title":"Circ: Cardiovascular Interventions"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0071","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1161\/CIRCULATIONAHA.120.050771","article-title":"Colchicine in patients with acute coronary syndrome: the Australian COPS randomized clinical trial","volume":"142","author":"Tong","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0072","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa2405922","article-title":"Colchicine in Acute Myocardial Infarction","volume":"392","author":"Jolly","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0073","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0074","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1056\/NEJMoa2027892","article-title":"Phase 3 trial of interleukin-1 trap rilonacept in recurrent pericarditis","volume":"384","author":"Klein","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0075","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.jacc.2025.07.064","article-title":"Targeting inflammation after acute myocardial infarction","volume":"86","author":"Imbesi","year":"2025","journal-title":"JACC"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0076","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105960","article-title":"The effects of interleukin-6-receptor inhibition on monocytes in STEMI: a substudy of the ASSAIL-MI trial","volume":"121","author":"Huse","year":"2025","journal-title":"eBioMedicine"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0077","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"The Lancet"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0078","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-021-00198-1","article-title":"Targeting inflammation in atherosclerosis - from experimental insights to the clinic","volume":"20","author":"Soehnlein","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0079","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1093\/eurheartj\/ehad304","article-title":"Novel mechanisms and therapeutic targets in atherosclerosis: inflammation and beyond","volume":"44","author":"Weber","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2024.102524","article-title":"Targeting inflammatory signaling pathways with SGLT2 inhibitors: Insights into cardiovascular health and cardiac cell improvement","volume":"49","author":"Alsereidi","year":"2024","journal-title":"Curr Prob Cardiol"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0081","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.jtha.2024.12.003","article-title":"New targets for antithrombotic medications: seeking to decouple thrombosis from hemostasis","volume":"23","author":"Barnes","year":"2025","journal-title":"J Thromb Haemostasis"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0082","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104473","article-title":"Blocking platelet glycoprotein VI (GPVI) as a promising antithrombotic treatment","volume":"30","author":"Li","year":"2025","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0083","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.bpj.2024.11.018","article-title":"GPVI-mediated thrombus stabilization of shear-induced platelet aggregates in a microfluidic stenosis","volume":"124","author":"Watson","year":"2025","journal-title":"Biophysical Journal"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0084","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s00392-025-02675-8","article-title":"Plasma chemokines indicate enhanced bleeding in patients with chronic coronary syndrome undergoing percutaneous coronary stenting","volume":"114","author":"Harm","year":"2025","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0085","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/jamacardio.2021.0475","volume":"6","author":"Mayer","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0086","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1016\/j.jtha.2023.07.018","article-title":"Amplified inhibition of atherosclerotic plaque-induced platelet activation by glenzocimab with dual antiplatelet therapy","volume":"21","author":"Alenazy","year":"2023","journal-title":"J Thromb Haemostasis"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0087","article-title":"Glenzocimab for reperfusion in the setting of endovascular therapy for brain infarction: GREEN study","author":"Mazighi","year":"2025","journal-title":"J NeuroIntervent Surg"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0088","doi-asserted-by":"crossref","unstructured":"Denorme F, Vanhoorelbeke K, De Meyer SF. von Willebrand factor and platelet glycoprotein Ib: a thromboinflammatory axis in stroke. Front Immunol 2019;10:2884. https:\/\/doi.org\/10.3389\/fimmu.2019.02884.","DOI":"10.3389\/fimmu.2019.02884"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0089","doi-asserted-by":"crossref","first-page":"7804","DOI":"10.3390\/ijms21207804","article-title":"Shear stress-induced activation of von Willebrand factor and cardiovascular pathology","volume":"21","author":"Okhota","year":"2020","journal-title":"IJMS"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0090","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1161\/CIRCULATIONAHA.107.724864","article-title":"First-in-human evaluation of anti-von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers","volume":"116","author":"Gilbert","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0091","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1182\/blood-2010-11-317859","article-title":"Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs","volume":"118","author":"Ulrichts","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0092","article-title":"In vitro assessment and phase I randomized clinical trial of anfibatide a snake venom derived anti-thrombotic agent targeting human platelet","volume":"11","author":"Li","year":"2021","journal-title":"GPIb\u03b1. Sci Rep"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0093","series-title":"Platelet Physiology I","first-page":"277","article-title":"Platelet protease-activated receptors","author":"Kendrick","year":"2025"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0094","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/rth2.12454","article-title":"Protease-activated receptors: an illustrated review","volume":"5","author":"Han","year":"2021","journal-title":"Res Pract Thromb Haemostasis"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0095","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1109719","article-title":"Thrombin-receptor antagonist vorapaxar in acute coronary syndromes","volume":"366","author":"Tricoci","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0096","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"Vorapaxar in the secondary prevention of atherothrombotic events","volume":"366","author":"Morrow","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0097","doi-asserted-by":"crossref","first-page":"12787","DOI":"10.1074\/jbc.R112.355461","article-title":"Turning receptors on and off with intracellular pepducins: new insights into g-protein-coupled receptor drug development","volume":"287","author":"O\u2019Callaghan","year":"2012","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0098","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1161\/ATVBAHA.115.306777","article-title":"Cell-penetrating pepducin therapy targeting par1 in subjects with coronary artery disease","volume":"36","author":"Gurbel","year":"2016","journal-title":"ATVB"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0099","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1161\/ATVBAHA.120.315168","article-title":"PAR1 (Protease-Activated Receptor 1) pepducin therapy targeting myocardial necrosis in coronary artery disease and acute coronary syndrome patients undergoing cardiac catheterization: a randomized, placebo-controlled, phase 2 study","volume":"40","author":"Kuliopulos","year":"2020","journal-title":"ATVB"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0100","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1161\/ATVBAHA.117.310104","article-title":"PAR4 (Protease-Activated Receptor 4) Antagonism with BMS-986120 inhibits human ex vivo thrombus formation","volume":"38","author":"Wilson","year":"2018","journal-title":"ATVB"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0101","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1161\/ATVBAHA.123.320448","article-title":"PAR4 antagonism in patients with coronary artery disease receiving antiplatelet therapies","volume":"44","author":"Nash","year":"2024","journal-title":"ATVB"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0102","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1161\/01.ATV.0000071347.69358.D9","article-title":"Signal transduction pathways mediated by PECAM-1: new roles for an old molecule in platelet and vascular cell biology","volume":"23","author":"Newman","year":"2003","journal-title":"ATVB"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0103","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00441-013-1779-3","article-title":"PECAM-1: regulator of endothelial junctional integrity","volume":"355","author":"Privratsky","year":"2014","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0104","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/jnis-2024-021694","article-title":"Preclinical in vitro and in vivo results of the new silk vista flow diverter with P8RI coating","volume":"17","author":"Cortese","year":"2025","journal-title":"J NeuroIntervent Surg"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0105","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1161\/STROKEAHA.120.030624","article-title":"CD31 mimetic coating enhances flow diverting stent integration into the arterial wall promoting aneurysm healing","volume":"52","author":"Cortese","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0106","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.jacc.2021.02.049","article-title":"Randomized trial of interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction","volume":"77","author":"Broch","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0107","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jama.297.1.43","article-title":"Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial","volume":"297","author":"Armstrong","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0108","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jama.2016.3609","article-title":"Effect of losmapimod on cardiovascular outcomes in patients hospitalized with acute myocardial infarction: a randomized clinical trial","volume":"315","author":"O\u2019Donoghue","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0109","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease","volume":"61","author":"Nidorf","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2026.03.058_bib0110","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2019","journal-title":"N Engl J Med"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914926002018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914926002018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T12:16:08Z","timestamp":1779970568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914926002018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":110,"alternative-id":["S0002914926002018"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2026.03.058","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond Percutaneous Coronary Intervention - Targeted Molecular Therapies for the Next Era of Coronary Care","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2026.03.058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}